NUVIGIL
What it isDopamine-reuptake-inhibiting wake-promoter; narcolepsy, sleep-apnea sleepiness, and shift-work disorder.
Why this oneAs modafinil's R-enantiomer, it sustains wakefulness later in the day from morning administration.
What limits itCYP3A4 induction can compromise hormonal contraception. Serious rash, insomnia, and misuse risk also matter.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Obstructive sleep apnea (excessive sleepiness) | adults | 150-250 mg QD (morning) | 150-250 mg QD | 250 mg QD |
| Narcolepsy | adults | 150-250 mg QD (morning) | 150-250 mg QD | 250 mg QD |
| Shift work disorder | adults | 150 mg QD (~1 h before shift) | 150 mg QD | 150 mg QD |
Renal Undefined
Hepatic Severe hepatic impairment: reduce dose.
Pregnancy Insufficient data; IUGR and spontaneous abortion reported; may cause fetal harm (animal data).
Lactation Undefined
NO BOXED WARNINGS
Principal riskIt induces CYP3A4 enough to fail oral contraceptives
Cost, est. cash$10–$300/month
Generic entry2012
Legacy pregnancy categoryC
Defining liabilitySerious rash, psychiatric activation and CYP-mediated interactions; misuse potential is present.

Open Armodafinil in the interactive console ↗

